WallStSmart

Guardian Pharmacy Services, Inc. (GRDN)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 4449% more annual revenue ($66.57B vs $1.46B). MRK leads profitability with a 4.8% profit margin vs 4.5%. GRDN trades at a lower P/E of 40.8x. GRDN earns a higher WallStSmart Score of 49/100 (D+).

GRDN

Hold

49

out of 100

Grade: D+

Growth: 7.3Profit: 6.0Value: 4.7Quality: 7.5
Piotroski: 3/9Altman Z: 5.18

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GRDN.

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GRDN4 strengths · Avg: 9.5/10
EPS GrowthGrowth
139.8%10/10

Earnings expanding 139.8% YoY

Altman Z-ScoreHealth
5.1810/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
24.0%9/10

Every $100 of equity generates 24 in profit

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

GRDN4 concerns · Avg: 3.5/10
Price/BookValuation
11.2x4/10

Trading at 11.2x book value

Revenue GrowthGrowth
2.2%4/10

2.2% revenue growth

Profit MarginProfitability
4.5%3/10

4.5% margin — thin

Operating MarginProfitability
3.5%3/10

Operating margin of 3.5%

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : GRDN

The strongest argument for GRDN centers on EPS Growth, Altman Z-Score, Return on Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : GRDN

The primary concerns for GRDN are Price/Book, Revenue Growth, Profit Margin. A P/E of 40.8x leaves little room for execution misses. Thin 4.5% margins leave little buffer for downturns.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GRDN scores higher overall (49/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Guardian Pharmacy Services, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Guardian Pharmacy Services, Inc. is a leading provider of specialized pharmacy solutions focused on the long-term care sector, servicing assisted living and skilled nursing facilities. Known for its commitment to personalized medication management and stringent quality standards, the company leverages advanced technology and deep pharmaceutical expertise to enhance patient outcomes. With an extensive operational presence across multiple states, Guardian is well-positioned to address the growing demand for customized pharmacy services, ensuring optimal operational efficiency for its healthcare partners in an evolving market.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?